Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538936 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL1338047 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL1571201 | 0.79 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1ALOX15 | |
| SCHEMBL1571986 | 0.79 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1ALOX15 | |
| SCHEMBL923501 | 0.78 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL496356 | 0.78 | HCRTR1 (0.43) | HCRTR1HCRTR2MAPK1 | |
| Hydrochloric Acid SCHEMBL1398882 | 0.78 | MAPK1 (0.48) | HCRTR1HCRTR2MAPK1ALOX15 | |
| SCHEMBL496272 | 0.77 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL983349 | 0.72 | HCRTR1 (0.42) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL12330231 | 0.71 | MAPK1 (0.43) | HCRTR1HCRTR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | HCRTR1 2/4885HCRTR2 1/4885MAPK1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.